Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma
/PRNewswire/ Flagship Pioneering, the bioplatform innovation company, today announced the unveiling of a new company – Sonata Therapeutics – to develop.
Sonata Therapeutics is developing drugs that reprogram cellular microenvironments to send signals intended to have curative effects. Cancer is the initial focus of the biotech, which Flagship Pioneering formed by combining two of its preclinical portfolio companies.